Trials / Conditions / Moderate to Severe Asthma

Moderate to Severe Asthma

14 registered clinical trials studyying Moderate to Severe Asthma — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase II Trial of RC1416 Injection in Asthma NCT07403487	Nanjing RegeneCore Biotech Co., Ltd.	Phase 2
Not Yet Recruiting	A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma NCT07372287	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 3
Recruiting	CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma NCT07241117	Washington University School of Medicine	Phase 4
Not Yet Recruiting	Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) NCT07191535	Foresee Pharmaceuticals Co., Ltd.	Phase 2
Completed	A Phase Ib Study of RC1416 Injection NCT06911866	Nanjing RegeneCore Biotech Co., Ltd.	Phase 1
Completed	A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China NCT06422663	AstraZeneca	—
Recruiting	Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping NCT06385236	University of California, San Diego	Phase 4
Recruiting	A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled NCT05851443	Incyte Corporation	Phase 2
Unknown	A Study of CM326 in Subjects With Moderate to Severe Asthma NCT05774340	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 2
Recruiting	A Study of CM310 in Subjects With Moderate to Severe Asthma NCT05761028	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 2 / Phase 3
Completed	Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With NCT05062759	AstraZeneca	Phase 3
Completed	Study of Multiple Ascending Dose of KBL693 in Healthy Participants NCT04307173	KoBioLabs	Phase 1
Completed	Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics NCT03556683	University of North Carolina, Chapel Hill	N/A
Completed	Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids NCT01603277	Humanigen, Inc.	Phase 2